Market Overview:
The global DPP-4 inhibitors market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of type 2 diabetes, rising awareness about diabetes and its treatment, and technological advancements in the field of DPP-4 inhibitors. Based on type, the global DPP-4 inhibitors market is segmented into sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin. Based on application, the market is segmented into hospitals and clinics. Geographically, the global DPP-4 inhibitors market is segmented into North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (China Japan India Australia South Korea) Middle East & Africa (South Africa Saudi Arabia UAE).
 Inhibitors Industry Outlook.svg)
Product Definition:
DPP-4 inhibitors are a type of drug that blocks the action of the DPP-4 enzyme. This enzyme is responsible for breaking down two particular peptides, GLP-1 and GIP. When these peptides are broken down, they lose their ability to stimulate the pancreas to produce insulin. By blocking the action of DPP-4, DPP-4 inhibitors allow these peptides to stay in circulation for longer periods of time, which can help improve blood sugar control in people with diabetes.
Sitagliptin:
The global sitagliptin, it's usage and growth factor in DPP-4 inhibitors market size was valued at USD 1.8 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the key factors driving growth for this market globally as well as in the U.
Saxagliptin:
Saxagliptin is an oral drug that inhibits DPP-4. DPP-4 is an enzyme responsible for removing the inhibitory peptide from the cell surface receptor, which results in increased levels of insulin and GLP-1 (glucose sensing protein). Saxagliptin was approved by the U.S.
Application Insights:
DPP-4 inhibitors are primarily used in the treatment of diabetes mellitus type 2. The increasing prevalence of diabetes and the failure of existing therapies to improve patient outcomes is expected to drive demand. According to a study conducted by WHO, it was estimated that globally around 90 million people were suffering from diabetes and this number is expected to reach 200 million by 2050.
The hospital segment held around 60% share in 2017 and this trend is anticipated to continue over the forecast period due largely on factors such as presence of advanced healthcare facilities coupled with growing incidences of chronic diseases like cancer, kidney disease & dialysis centers etc. DPP-4 inhibitors are also used for other indications such as obesity, hyperlipidemia (high cholesterol level), gouty arthritis (reactive arthritis) etc.
Regional Analysis:
North America dominated the global DPP-4 inhibitors market in 2017 with a revenue share of over 40%. The growth is attributed to the presence of key players, such as Takeda Pharmaceuticals and Novartis AG. In addition, favorable reimbursement policies for diabetes drugs in this region are also expected to boost market growth during the forecast period. For instance, according to an article published in WebMD LLC., November 2016 issue, insulin has been approved by Medicare Part B since April 2015 while before that it was only covered when prescribed by a doctor.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising patient awareness levels regarding new treatment options and increasing healthcare expenditure levels especially due to rising government initiatives & spending.
Growth Factors:
- Increasing incidence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily attributed to the changing lifestyle and dietary habits. According to the World Health Organization (WHO), the number of people with diabetes has almost quadrupled since 1980 and is expected to reach 642 million by 2040. This will create a large pool of patients who will require treatment, thereby driving the growth of DPP-4 inhibitors market.
- Rising awareness about type 2 diabetes: There is a growing awareness among people about type 2 diabetes and its associated risks. This has led to an increase in the number of people seeking diagnosis and treatment for this condition, thereby propelling the growth of DPP-4 inhibitors market.
- Growing demand for novel therapies: Patients are increasingly looking for novel therapies that can effectively manage their condition with minimal side effects. DPP-4 inhibitors offer an efficacious alternative to traditional treatments, thus fueling their demand in the marketplaces across regions worldwide .
Scope Of The Report
Report Attributes
Report Details
Report Title
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Research Report
By Type
Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
By Application
Hospitals, Clinics
By Companies
Merck, Eli Lilly, AstraZenica, Boehringer Ingelheim, Takeda Pharmaceutical Company, BMS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report Segments:
The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market is segmented on the basis of:
Types
Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Eli Lilly
- AstraZenica
- Boehringer Ingelheim
- Takeda Pharmaceutical Company
- BMS
 Inhibitors Market Overview.svg)
Highlights of The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sitagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
- Vildagliptin
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dipeptide Peptidase 4 (DPP-4) Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
DPP-4 inhibitors are medications that block the activity of DPP-4. This can reduce the amount of peptides that are released from cells and can lead to improved patient outcomes.
Some of the major companies in the dipeptide peptidase 4 (dpp-4) inhibitors market are Merck, Eli Lilly, AstraZenica, Boehringer Ingelheim, Takeda Pharmaceutical Company, BMS.
The dipeptide peptidase 4 (dpp-4) inhibitors market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Supply Chain
4.5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Forecast
4.5.1. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Absolute $ Opportunity
5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Type
5.3.1. Sitagliptin
5.3.2. Saxagliptin
5.3.3. Linagliptin
5.3.4. Alogliptin
5.3.5. Vildagliptin
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Demand Share Forecast, 2019-2026
9. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Type
9.7.1. Sitagliptin
9.7.2. Saxagliptin
9.7.3. Linagliptin
9.7.4. Alogliptin
9.7.5. Vildagliptin
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Type
10.7.1. Sitagliptin
10.7.2. Saxagliptin
10.7.3. Linagliptin
10.7.4. Alogliptin
10.7.5. Vildagliptin
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Demand Share Forecast, 2019-2026
11. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Type
11.7.1. Sitagliptin
1.7.2. Saxagliptin
11.7.3. Linagliptin
11.7.4. Alogliptin
11.7.5. Vildagliptin
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Demand Share, 2019-2026
12. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Type
12.7.1. Sitagliptin
12.7.2. Saxagliptin
12.7.3. Linagliptin
12.7.4. Alogliptin
12.7.5. Vildagliptin
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Volume Forecast by Type
13.7.1. Sitagliptin
13.7.2. Saxagliptin
13.7.3. Linagliptin
13.7.4. Alogliptin
13.7.5. Vildagliptin
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market: Market Share Analysis
14.2. Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors and Customers
14.3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AstraZenica
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Boehringer Ingelheim
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Takeda Pharmaceutical Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BMS
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
